A Pilot Study of Pre-Operative, Single-Dose Ipilimumab, Nivolumab and Cryoablation in Early Stage/Resectable Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Early breast cancer
- Focus Adverse reactions
- 01 Nov 2017 Planned number of patients changed from 6 to 5.
- 01 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Mar 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.